The U.S. FDA approved two oral therapies for gonorrhea—Innoviva’s zoliflodacin (Nuzolvence) and GSK’s gepotidacin (Blujepa)—broadening antibiotic options against a pathogen with rising resistance. Both agents received expedited regulatory pathways, including priority review and qualified infectious disease product designations, reflecting public‑health urgency. Approvals deliver orally administered alternatives to current standard regimens and could alter outpatient management and stewardship strategies. Implementation will hinge on updated treatment guidelines and surveillance for emergent resistance to the new agents.